Search results for "BirA"

showing 10 items of 32 documents

Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel: a retrospective study.

2017

The aim of this study was to evaluate abiraterone's efficacy in Italian patients affected with metastatic prostate cancer progressing after treatment with docetaxel. We conducted a retrospective analysis of 60 patients. Prostate-specific antigen (PSA) reduction in serum was the primary endpoint for evaluating the efficacy of abiraterone in combination with prednisone treatment, whereas reduced pain, safety, progression-free survival, response rate, and overall survival (OS) were secondary endpoints. A significant correlation was noticed between PSA response and OS. Further, the Index Bravais-Pearson (r) correlation allowed us to observe a significant negative interdependence between PSA res…

0301 basic medicineOncologyMalemedicine.medical_specialtyCancer ResearchDocetaxelprostatic neoplasm03 medical and health sciencesProstate cancer0302 clinical medicinePrednisoneInternal medicineabirateroneAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansPharmacology (medical)Neoplasm MetastasisSurvival rateAgedRetrospective StudiesPharmacologyAged 80 and overbusiness.industryandrogen antagonistRetrospective cohort studyMiddle AgedProstate-Specific Antigenmedicine.diseasedrug therapyProstate-specific antigenProstatic Neoplasms Castration-Resistant030104 developmental biologyDocetaxelTolerabilitymetastatic castration-resistant prostate cancerOncology030220 oncology & carcinogenesisPrednisoneAndrostenesKallikreinsTaxoidsbusinessmedicine.drugAnti-cancer drugs
researchProduct

Development of polypeptide-based therapeutics for the treatment of castration resistant prostate cancer

2019

El cáncer de próstata (CaP) es el segundo cáncer más frecuente en los hombres. Los estudios han establecido el gen de fusión (T2E) compuesto por TMPRSS2 (serina proteasa dependiente de andrógenos) y ERG (factor de transcripción de la familia ETS) como un biomarcador potencial de CaP. La progresión en el CaP incluye tanto el receptor de andrógenos (AR) como el receptor del factor de crecimiento de insulina 1 (IGF-1R), y el tratamiento con un anticuerpo anti-IGF-1R (AVE1642) ha demostrado un gran potencial en el tratamiento de los pacientes con CaP T2E-positivos. Por ello, el desarrollo de terapias personalizadas basadas en polímeros terapéuticos puede favorecer el tratamiento de CaP para un …

:CIENCIAS DE LA VIDA::Biología humana [UNESCO]castration resistant prostate cancerpolymer antibody conjugatepolymer therapeuticconfocal microscopy:CIENCIAS DE LA VIDA::Biología molecular [UNESCO]combination therapyabirateroneantibodiescell signalingtumor microenvironmentUNESCO::CIENCIAS DE LA VIDA::Biología molecular:CIENCIAS DE LA VIDA::Bioquímica [UNESCO]orthotopic mice modelflow cytometryUNESCO::CIENCIAS DE LA VIDA::BioquímicaUNESCO::CIENCIAS DE LA VIDA::Biología celularprostate cancernanomedicineUNESCO::QUÍMICA::Otras especialidades químicas:CIENCIAS DE LA VIDA::Biología celular [UNESCO]UNESCO::QUÍMICA::BioquímicaUNESCO::CIENCIAS DE LA VIDA::Biología humanacell trafficking:QUÍMICA::Otras especialidades químicas [UNESCO]:QUÍMICA::Bioquímica [UNESCO]
researchProduct

Geometry of the projectivization of ideals and applications to problems of birationality

2018

In this thesis, we interpret geometrically the torsion of the symmetric algebra of the ideal sheaf I_Z of a scheme Z defined by n+1 equations in an n-dimensional variety. This is equivalent to study the geometry of the projectivization of I_Z. The applications of this point of view concern, in particular, the topic of birational maps of the projective space of dimension 3 for which we construct explicit birational maps that have the same algebraic degree as their inverse, free and nearly-free curves for which we generalise a characterization of free curves by extending the notion of Milnor and Tjurina numbers. We tackle also the topic of homaloidal hypersurfaces, our original motivation, fo…

Algebraic geometrySyzygiesBirational mapsTransformations birationellesHypersurfaces homaloïdesGéométrie algébriqueHomaloidal hypersurfaces[MATH.MATH-AG] Mathematics [math]/Algebraic Geometry [math.AG][MATH.MATH-AG]Mathematics [math]/Algebraic Geometry [math.AG]Commutative algebraSingularitiesSingularitésAlgèbre commutative
researchProduct

Xarxes agroecològiques locals com a resposta social al problema global de l'alimentació: El cas d'Alcoi

2015

En la primera part de l'article, es presenta de manera contextualitzada el panorama desolador de l'alimentació al món. En la segona part, s'explica detalladament la proposta local de creació i posada en marxa d'una xarxa agroecològica a la població d'Alcoi, que ve funcionant des de l'any 2009. Per últim, conclou l'article destacant alguns reptes de futur (no tots, és clar) amb els quals ens trobem no només els membres que formem part de la xarxa agroecològica alcoiana, sinó també la resta de persones que formem la societat.

AlimentacióGrups de consumProximitatLocalSobirania alimentàriaCooperacióInnovació social
researchProduct

Stereotactic body radiotherapy in oligoprogressive metastatic castration-resistant prostate cancer during abiraterone or enzalutamide

2022

Introduction: This monocentric, single-arm, retrospective study investigated the role of stereotactic body radiotherapy in patients with metastatic castration resistant prostate cancer who experienced oligoprogression during androgen receptor targeted agents. Methods: We retrospectively enrolled metastatic castration resistant prostate cancer patients treated with androgen receptor targeted agents between December 2016 and January 2022. All patients experienced an oligoprogression (defined as the appearance and/or the progression of ⩽5 bone or nodal or soft tissue metastases) during treatment with androgen receptor targeted agents and received stereotactic body radiotherapy upon oligoprogre…

Cancer ResearchenzalutamideOncologyStereotactic body radiotherapyabirateronemetastatic castration resistant prostate cancerGeneral Medicineoligometastatic diseaseSettore MED/36 - Diagnostica Per Immagini E RadioterapiaTumori Journal
researchProduct

Actions de tores algébriques sur des corps de caractéristique zéro

2023

Over an algebraically closed field of characteristic zero, normal affine varieties endowed with an effective torus action were described by Altmann and Hausen in 2006 by a geometrico-combinatorial presentation.Using Galois descent tools, we extend this presentation to the case where the ground field is an arbitrary field of characteristic zero. In this context, the acting torus may be non split and may have non-trivial torsors, thus we need additional data to encode such varieties. We provide some situations where the generalized Altmann-Hausen presentation simplifies. For instance, if the acting torus is split, we recover mutatis mutandis the original Altmann-Hausen presentation. Finally, …

Convex geometryAction of algebraic torusActions de tores algébriquesStructures et formes réellesGéométrie birationnelle[MATH.MATH-GM] Mathematics [math]/General Mathematics [math.GM]Birational geometryGéométrie convexeReal structures and real forms
researchProduct

Standard classes on the blow-up of $\mathbb{P}^n$ at points in very general position

2012

Linear systems fat points birational transformationsSettore MAT/03 - Geometria
researchProduct

Combining anticancer drugs with osteoprotective agents in prostate cancer—A contemporary update

2018

Recently, a plethora of life-prolonging cytotoxic, next-generation hormonal, immunotherapeutical as well as radionuclide therapies has emerged as a standard care for metastasized castration-resistant prostate cancer. Being strikingly effective in cancer control, these novel therapies might in fact exert a beneficial impact on skeletal events. Therefore, combining anticancer drugs with osteoprotective agents might lead to additional clinical advantage but must be weighed against simultaneously exposing patients to serious toxicities. In addition, further survival prolongation by changing treatment paradigm in both metastasized hormone-sensitive and nonmetastatic castration-resistant disease …

MaleOncologymedicine.medical_specialtyCombination therapyCost effectivenessUrologyAntineoplastic AgentsDiseaselaw.invention03 medical and health sciencesProstate cancerchemistry.chemical_compound0302 clinical medicineRandomized controlled triallawInternal medicinemedicineHumans030212 general & internal medicineBone Density Conservation Agentsbusiness.industryAbiraterone acetateProstatic NeoplasmsBone metastasismedicine.diseaseZoledronic acidOncologychemistry030220 oncology & carcinogenesisDrug Therapy Combinationbusinessmedicine.drugUrologic Oncology: Seminars and Original Investigations
researchProduct

Health-related Quality of Life in Patients with Advanced Prostate Cancer: A Systematic Review

2021

Abstract Context The assessment of “soft” endpoints such as health-related quality of life (HRQOL) is increasingly relevant when evaluating the optimal treatment sequence of novel therapeutic options in patients with advanced prostate cancer (PCa). Objective To systematically review contemporary data regarding HRQOL outcomes in patients with advanced PCa. Evidence acquisition A systematic review of the literature published between January 2011 and March 2019 was performed using the PubMed/Medline Database. In total, 873 articles were screened, and 14 articles including 12 661 patients were selected for synthesis and included in the current analysis according to the Preferred Reporting Items…

MaleOncologymedicine.medical_specialtyUrologyHealth-related quality of lifeAbiraterone Acetate030232 urology & nephrologyContext (language use)Androgen deprivation therapy03 medical and health scienceschemistry.chemical_compoundMetastatic prostate cancer0302 clinical medicineQuality of lifeInternal medicineHumansMedicineEnzalutamideEuropean Organization for Research and Treatment of Cancer Quality of Life QuestionnaireCastration-resistant prostate cancerbusiness.industryAdvanced prostate cancerApalutamideAbiraterone acetateFunctional Assessment of Cancer Therapy-ProstateAndrogen AntagonistsAdvanced prostate cancer; Castration-resistant prostate cancer; European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; European Quality of Life 5-Dimensions; Functional Assessment of Cancer Therapy-Prostate; Health-related quality of life; Metastatic prostate cancerhumanitiesEuropean Quality of Life 5-DimensionsClinical trialProstatic Neoplasms Castration-ResistantSystematic reviewchemistry030220 oncology & carcinogenesisAndrogensQuality of LifebusinessOrchiectomy
researchProduct

A new species of Charinus Simon, 1892 (Amblypygi, Charinidae) from termite nests in French Guiana

2015

The genus Charinus is represented by 51 species, distributed in all tropical regions. Their small size allows them to use a wide range of micro-habitats, from caves, litter to insect nests. The new species C. sillami sp. nov. was found into termite nests of three different species: Neocapritermes taracua, Spinitermes sp. and Embiratermes neotenicus. Only Paracharon caecus (Paleoamblypygi: Paracharontidae) was previously known to be associated with Isoptera. Eleven species of Charinus were previously known from Northern South America. Charinus sillami sp. nov. is the second species of the genus occurring in French Guiana. An updated key of Northern South-American species is provided.

Malemedia_common.quotation_subjectInsectAmblypygiCaveArachnidaAnimalsBody SizeEcosystemEcology Evolution Behavior and Systematicsmedia_commongeographygeography.geographical_feature_categorybiologyEcologyNeocapritermes taracuaAnimal StructuresTropicsOrgan Sizebiology.organism_classificationFrench GuianaCharinidaeFemaleAnimal Science and ZoologyTaxonomy (biology)Animal DistributionEmbiratermes neotenicusZootaxa
researchProduct